Merck KGaA

Merck KGaA

MKKGY - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$65.04B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Merck KGaAMerck KGaA27.41.47%6%3.50.4

Earnings Call Q3 2026

November 12, 2026 - AI Summary

Q3 performance: solid growth with portfolio tailwinds; profitable organic growth continued - Group organic sales growth accelerated to 5.1% in Q3 (after 4.1% in Q2), supported mainly by Life Science and Electronics; Healthcare improved sequentially despite headwinds. - Life Science: +6.1% organic; Process Solutions +10.5% organic (tariff-refund-adjusted 12.6%), Discovery Solutions +1.7% organic (tariff-refund-adjusted 2.4%), Advanced Solutions +4.3% organic. - Healthcare: Rare Diseases contributed to organic growth (mid-double-digit %); Cardiometabolic and Fertility/Endocrinology each mid-single-digit growth; Specialty Care weakened due to Mavenclad U.S. loss of exclusivity accelerating in Q3. - Electronics: Organic growth reached 13% in Q3; Semiconductor Solutions +19% organic (advanced-node ramp), Optronics ~stable but still pressured by consumer electronics demand softness.
Strategic actions (good/surprising mix of growth + portfolio “sharpening”): acquisitions/divestments + capacity investments - Acquisition (positive, growth-oriented): planned Silence Therapeutics acquisition in October; expected close Q1 2027. Would add Divesiran (Phase III-ready siRNA) for polycythemia vera, aligned with Targeted Specialty & Rare Diseases; also seen as a route to expand into Hematology. - Divestment (negative near-term optics but strategic): planned divestment of CDMO business to Lonza; expected close mid-2027. Management cited lower capital intensity and portfolio focus. - Close nearing (positive): Bio-Techne acquisition is “a few steps away” from closing; assumed to be accretive to sales and margins and to contribute in 2026 (actual closing date not set). - Footprint/capacity investments (support long-term growth): new Asia Pacific bioprocessing production center in Daejeon (>EUR 300m), US semiconductor R&D in Sheboygan (38k sq ft; part of $200m multiyear), and EU BioReliance testing facility in Darmstadt (EUR 25m).
Full-year 2026 guidance upgraded again (key numbers investors care about) - Group organic net sales now expected +3% to +4% (up from +1% to +3%). - FX headwind improving: now expected -1% to 0% vs -2% to 0% previously. - Net sales (reported) now guided to ~EUR 21.5bn to 21.9bn (previously EUR 21.0bn to 21.8bn), now also reflecting Bio-Techne portfolio effect for December (assumed; closing timing may shift). - EBITDA pre: EUR 6.2bn to 6.4bn (up from EUR 5.9bn to 6.3bn) → reflects organic growth +3% to +5%. - EPS pre: EUR 8.30 to 8.70 (up from EUR 7.90 to 8.60). - Segment guidance highlights: - Life Science organic sales +6% to +7% (midpoint absolute increases); EBITDA pre organic +6% to +8%. - Healthcare organic sales -3% to -2% (improving vs prior range due to Mavenclad U.S. assumed 0 sales as of November); EBITDA pre ~EUR 2.9bn to 3.0bn. - Electronics organic sales +10% to +11% (up from prior); EBITDA pre ~EUR 1.1bn; strong operating leverage expected.

Exclusive for Stockcircle Pro members

Sign upSign Up
$13.42

Current Fair Value

57.9% downside

Overvalued by 57.9% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$65.04 Billion
Enterprise Value$75.13 Billion
Annual dividend$0.51
Dividend yield1.47%
Earnings per Share$1.15
Beta0.81
Outstanding Shares2,173,889,390

Return

Return on Equity6.12%ROE
Return on Assets3.58%
Return on Invested Capital7.55%

Valuation & Multiples

P/E Ratio27.45P/E Ratio
PEG-54.78PEG
Price to Sales3.54Price to Sales
Price to Book Ratio2.28Price to Book Ratio
Enterprise Value to Revenue3.5
Enterprise Value to EBIT22.27
Enterprise Value to Net Income39
Total Debt to Enterprise0.18
Debt to Equity0.43Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 12, 2026
EPS
$0.24
Est. $0.50
Revenue
$6.23 B
Est. $6.12 B

Next Earnings Call

Expected Date
March 4, 2027
EPS Estimate
$0.43
Consensus analyst estimate
Revenue Estimate
$6.17 B
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Merck KGaA

62,461 employees
CEO: Kai Beckmann

Merck KGaA is a venerable science and technology enterprise, headquartered in Darmstadt, Germany, where it was established in 1668. Operating as a subsidiary of E. Merck KG, the company organizes its diverse activities across three princ...

Questions & Answers